Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 934729, 7 pages
http://dx.doi.org/10.1155/2014/934729
Research Article

The Role of Genetic Factors and Kidney and Liver Function in Glycemic Control in Type 2 Diabetes Patients on Long-Term Metformin and Sulphonylurea Cotreatment

1General Hospital Trbovlje, Rudarska cesta 9, 1420 Trbovlje, Slovenia
2Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia
3Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Zaloška cesta 2, 1000 Ljubljana, Slovenia

Received 28 February 2014; Revised 18 May 2014; Accepted 21 May 2014; Published 9 June 2014

Academic Editor: Tomohito Gohda

Copyright © 2014 Jasna Klen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. R. Erlich, D. C. Slawson, and A. Shaughnessy, “Diabetes update: long-term treatment of adults,” FP Essentials, vol. 408, pp. 14–19, 2013. View at Google Scholar · View at Scopus
  2. G. Rena, E. R. Pearson, and K. Sakamoto, “Molecular mechanism of action of metformin: old or new insights?” Diabetologia, vol. 56, no. 9, pp. 1898–1906, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Y. Sin, J. Y. Kim, and K. H. Jung, “Total cholesterol, high density lipoprotein and triglyceride for cardiovascular disease in elderly patients treated with metformin,” Archives of Pharmacal Research, vol. 34, no. 1, pp. 99–107, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. S. E. Inzucchi, R. M. Bergenstal, J. B. Buse et al., “Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD),” Diabetologia, vol. 55, no. 6, pp. 1577–1596, 2012. View at Google Scholar
  5. O. Zolk, “Disposition of metformin: variability due to polymorphisms of organic cation transporters,” Annals of Medicine, vol. 44, no. 2, pp. 119–129, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Shu, C. Brown, R. A. Castro et al., “Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics,” Clinical Pharmacology and Therapeutics, vol. 83, no. 2, pp. 273–280, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. G. G. Graham, J. Punt, M. Arora et al., “Clinical pharmacokinetics of metformin,” Clinical Pharmacokinetics, vol. 50, no. 2, pp. 81–98, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. O. Zolk, “Current understanding of the pharmacogenomics of metformin,” Clinical Pharmacology and Therapeutics, vol. 86, no. 6, pp. 595–598, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. V. Tzvetkov, S. V. Vormfelde, D. Balen et al., “The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin,” Clinical Pharmacology and Therapeutics, vol. 86, no. 3, pp. 299–306, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Lozano, E. Herraez, O. Briz et al., “Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology,” BioMed Research International, vol. 2013, Article ID 692071, 13 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Otsuka, T. Matsumoto, R. Morimoto, S. Arioka, H. Omote, and Y. Moriyama, “A human transporter protein that mediates the final excretion step for toxic organic cations,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 50, pp. 17923–17928, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Tsuda, T. Terada, T. Mizuno, T. Katsura, J. Shimakura, and K.-I. Inui, “Targeted disruption of the multidrug and toxin extrusion 1 (Mate1) gene in mice reduces renal secretion of metformin,” Molecular Pharmacology, vol. 75, no. 6, pp. 1280–1286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Motohashi and K.-I. Inui, “Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney,” AAPS Journal, vol. 15, no. 2, pp. 581–588, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Kerb, U. Brinkmann, N. Chatskaia et al., “Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences,” Pharmacogenetics, vol. 12, no. 8, pp. 591–595, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Shu, S. A. Sheardown, C. Brown et al., “Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action,” Journal of Clinical Investigation, vol. 117, no. 5, pp. 1422–1431, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. L. Becker, L. E. Visser, R. H. N. van Schaik, A. Hofman, A. G. Uitterlinden, and B. H. C. Stricker, “Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus,” Pharmacogenomics Journal, vol. 9, no. 4, pp. 242–247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Chen, M. Takizawa, E. Chen et al., “Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function,” Journal of Pharmacology and Experimental Therapeutics, vol. 335, no. 1, pp. 42–50, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Umamaheswaran, R. G. Praveen, A. S. Arunkumar, A. K. Das, D. G. Shewade, and C. Adithan, “Genetic analysis of OCT1 gene polymorphisms in an Indian population,” Indian Journal of Human Genetics, vol. 17, no. 3, pp. 164–168, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. A. T. Nies, H. Koepsell, S. Winter et al., “Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver,” Hepatology, vol. 50, no. 4, pp. 1227–1240, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Shikata, R. Yamamoto, H. Takane et al., “Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin,” Journal of Human Genetics, vol. 52, no. 2, pp. 117–122, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Zhou, C. Bellenguez, C. C. A. Spencer et al., “Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes,” Nature Genetics, vol. 43, no. 2, pp. 117–120, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. “Standards of medical care in diabetes-2010,” Diabetes Care, vol. 33, supplement 1, pp. S11–S61, 2010.
  23. “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 36, supplement 1, pp. S67–S74, 2013.
  24. J. Klen, V. Dolzan, and A. Janez, “CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients,” European Journal of Clinical Pharmacology, vol. 70, no. 4, pp. 421–428, 2014. View at Publisher · View at Google Scholar
  25. P. E. Cryer, “Defining and reporting hypoglycemia in diabetes: a report from the American diabetes association workgroup on hypoglycemia,” Diabetes Care, vol. 28, no. 5, pp. 1245–1249, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. E. R. Seaquist, J. Anderson, B. Childs et al., “Hypoglycemia and diabetes: a report of aworkgroup of the American diabetes association and the endocrine society,” Diabetes Care, vol. 36, no. 5, pp. 1384–1395, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and D. Roth, “A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation,” Annals of Internal Medicine, vol. 130, no. 6, pp. 461–470, 1999. View at Google Scholar · View at Scopus
  28. A. S. Levey, K.-U. Eckardt, Y. Tsukamoto et al., “Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO),” Kidney International, vol. 67, no. 6, pp. 2089–2100, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. M. L. Becker, L. E. Visser, R. H. N. Van Schaik, A. Hofman, A. G. Uitterlinden, and B. H. C. Stricker, “Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response,” Pharmacogenetics and Genomics, vol. 20, no. 1, pp. 38–44, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. I. Tkáč, L. Klimčáková, M. Javorský et al., “Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 15, no. 2, pp. 189–191, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Zhou, L. A. Donnelly, C. H. Kimber et al., “Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study,” Diabetes, vol. 58, no. 6, pp. 1434–1439, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. S. E. Kahn, S. M. Haffner, M. A. Heise et al., “Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy,” The New England Journal of Medicine, vol. 355, no. 23, pp. 2427–2443, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. J. K. Duong, S. S. Kumar, C. M. Kirkpatrick et al., “Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function,” Clinical Pharmacokinetics, vol. 52, no. 5, pp. 373–384, 2013. View at Publisher · View at Google Scholar
  34. A. Kooy, J. De Jager, P. Lehert et al., “Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus,” Archives of Internal Medicine, vol. 169, no. 6, pp. 616–625, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Ji, H. Li, X. Guo, Y. Li, R. Hu, and Z. Zhu, “Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial,” PLoS ONE, vol. 8, no. 2, Article ID e57222, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. S. S. Lund, L. Tarnow, A. S. Astrup et al., “Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes,” Diabetes, Obesity and Metabolism, vol. 11, no. 10, pp. 966–977, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Tarasova, I. Kalnina, K. Geldnere et al., “Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients,” Pharmacogenetics and Genomics, vol. 22, no. 9, pp. 659–666, 2012. View at Publisher · View at Google Scholar · View at Scopus